- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Shiela Plasencia Previews the COA 2023 Community Oncology Conference
Shiela Plasencia, director of practice support at the Community Oncology Alliance, shares what she's looking forward to at the 2023 Community Oncology Conference.
Here's what to look forward to at the Community Oncology Alliance (COA) 2023 Community Oncology Conference, which will be held March 22-24, in Kissimee, Florida.
Transcript
What are you looking forward to the most at the COA 2023 Community Oncology Conference?
Seeing everyone! It's just it's still great to be out and be able to network and collaborate. And we've got some great topics coming this year. I think it's going to be super exciting to hear about the different conference sessions. But really, it's great just to see everybody and be in person again.
Are there any speakers or panel topics you're particularly looking forward to, that you would recommend to people attending the conference?
Judy [Alberto, MHA, RPh, BCOP, director of Clinical Initiatives at COA] has got a panel on value-based enterprise that I think is very, very interesting. It's a fairly new topic. I'm really excited about that panel.
And then it's also our 20th anniversary. There's a lot of excitement around that, and a lot of our past presidents will be there.
And just the path that community oncology has taken in the past 20 years, it's just kind of great to reemphasize that, and look and see where we were, what we've gotten to now, and what we have in front of us.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
